Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Whitehawk Therapeutics, Inc. Common Stock

WHWK

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

Last trade $3.05
Day change +$0.04 (+1.33%)
Day range $2.92 – $3.06
Volume 362,245
Market cap $178M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$177.62M
Price / earnings
—
Price / book
1.09×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.21×

Profitability

Earnings per share
-$1.41
Return on assets
-48.03%
Return on equity
-51.13%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
16.47×
Quick ratio
16.47×
Cash ratio
6.61×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$73.65M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for WHWK, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$0$0$0$0$0$0$7.15M
Cost of revenue$0$0$0$0$0$0$760K
Gross profit$0$0$0$0$0$0$6.39M
Selling, general and administrative$4.81M$5.22M$6.29M$5.87M$5.2M$5.94M$12.82M
Research and development$18.14M$12.89M$17.23M$19.02M$14.35M$48.81M$8.79M
Total operating expenses$22.94M$18.11M$23.52M$24.89M$19.55M$54.75M$21.6M
Operating income-$22.94M-$18.11M-$23.52M-$24.89M-$19.55M-$54.75M-$15.22M
Interest expense$0$0$0$0$0$0$0
Income before taxes-$21.21M-$16.64M-$22.19M-$23.25M-$17.75M-$52.62M$73.02M
Income taxes$0$0$0$0$0$0$0
Net income-$21.21M-$16.64M-$22.19M-$23.25M-$17.75M-$52.62M$73.02M
Net income attributable to common shareholders-$21.21M-$16.64M-$22.19M-$23.37M-$17.75M-$52.62M$73.02M
EBITDA-$22.94M-$18.11M-$23.52M-$24.89M-$19.54M-$54.73M-$15.16M
Basic earnings per share-$0.23-$0.20-$0.32-$0.34-$0.26-$0.76$1.84
Diluted earnings per share-$0.23-$0.20-$0.32-$0.34-$0.26-$0.76$1.83

Recent news

Company coverage with links to the original publishers.

Publication times in UTC

No recent company news found.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.